Vimal Mehta, Ph.D.

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development and corporate fundraising. He is a Co-founder, Chairman of the Board and Chief Executive Officer of BioXcel Corporation. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at Inpharmatica Ltd. and Jubilant Life Sciences. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation. Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in chemistry at the University of Montpellier, France.

Frank D. Yocca, Ph.D.

Frank D. Yocca, Ph.D.

Chief Scientific Officer

Dr. Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high performance, world-class teams in drug discovery and development whose efforts have resulted in a number of prominent neuroscience products including Buspar®, Serzone® Abilify® and Heltioz®. Frank has held leadership roles at AstraZeneca and Bristol Myers Squibb. He is a recognized scientific leader in the neuroscience community and member of the Institute of Medicine of the National Academy of Science, and a Fellow of the American College of Neuropsychopharmacology. He has 45 referred articles, 96 abstracts and 65 invited presentations. Dr. Yocca holds a B.S. in biochemistry from Manhattan College, as well as an M.S. in pharmacology and a Ph.D. in neuropharmacology from St. John’s University.

Vincent J.O’Neill M.D.

Vincent J.O’Neill M.D.

Senior Vice President & Chief Medical Officer

Dr. O’Neill has proven expertise in therapeutic and diagnostic product development and has held senior leadership roles at global pharmaceutical companies, including Sanofi, Genentech and GlaxoSmithKline. Most recently, he served as Chief Medical Officer at Mirna Therapeutics and Exosome Diagnostics, where he oversaw global product development and medical affairs. At both Genentech and GlaxoSmithKline, he managed the clinical and biomarker development programs of several oncology therapeutic candidates. He was instrumental in the expanded approvals of Genentech’s oncology therapeutics, Avastin® and Tarceva®. At GSK, he oversaw the signal transduction discovery unit and led the first IND application and clinical trial of the MEK inhibitor, MEKINIST®. He has authored several peer-reviewed publications and conference presentations. Dr. O’Neill is also a member of the Royal College of Physicians. He received his M.D. and B.Sc. in molecular pathology from the University of Glasgow, Scotland.

Reina Benabou, M.D., Ph.D.

Reina Benabou, M.D., Ph.D.

Senior Vice President & Chief Development Officer

Dr. Benabou has over 20 years of experience in directing drug development programs and implementing medical affairs strategies for product commercialization in neurology and psychiatry.

Prior to joining BTI, Dr. Benabou held numerous leadership roles at leading biopharma companies, including at Pfizer as Head of Global Medical Product Evaluation and in other principal medical affairs roles, at Novartis as VP & World Wide Medical Head for the Neuroscience Franchise, and most recently at Cognivue as Chief Medical Officer. She has built and led a variety of U.S. and global high performing development, medical, regulatory and safety teams responsible for the commercialization of multiple products, such as SUBOXONE® for the treatment of opioid drug addiction, GEODON® for the treatment of schizophrenia and manic symptoms of bipolar disorder, LYRICA® for the treatment of neuropathic pain in diabetes, fibromyalgia and SCI and to control seizures, and GILENYA® for the treatment of relapsing forms of multiple sclerosis. Dr. Benabou held academic appointments in the Neurology Departments of Mount Sinai School of Medicine and Columbia University in New York. She holds an M.D. from the Universidade de São Paulo and a Ph.D. in Neurological Sciences from the University of Montreal, Canada.

Chetan Lathia Ph.D.

Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

Dr. Lathia has over 28 years of experience in clinical pharmacology, nonclinical development, and regulatory affairs at both large and small biopharma companies. He has co-led the IND submissions for a number of new molecular entities and eight new drug applications (NDA) / biologics license applications (BLA) in the US, Europe, Japan, China, and other countries. In addition to presenting clinical pharmacology & clinical strategy at meetings with drug regulators, he has made presentations to the Special Advisory Group (SAG) of the European Medicines Agency and an advisory meeting held by Taiwanese regulators. Dr. Lathia has delivered presentations to the Food and Drug Administration on invitation from the agency’s Office of Clinical Pharmacology.

Most recently, Dr. Lathia served as the VP and Head of Clinical Pharmacology at Intarcia Therapeutics where he was responsible for leading the pharmacokinetics (PK)/pharmacodynamics (PD), immunogenicity and bioanalytical strategy. Prior to that, Dr. Lathia served as the Executive Director, Clinical Pharmacology at Alexion Pharmaceuticals where he led the global clinical and nonclinical PK/PD, pharmacometrics, and bioanalytics functions. Previously, Dr. Lathia served as the Global Head, Oncology Biomarkers and Pharmacokinetics and as the Global Clinical Pharmacology Leader for Nexavar at Bayer. Prior to this, he was a Senior Research Associate at Parke-Davis Research where he co-led drug metabolism, nonclinical & clinical PK functions for the oncology & cardiovascular portfolio.

Dr. Lathia earned a doctorate in pharmacokinetics from Virginia Commonwealth University and a bachelor’s degree in pharmacy, with a gold medal in pharmacology from L M College of Pharmacy, India.

Richard I. Steinhart

Richard I. Steinhart

Chief Financial Officer & Vice President

Mr. Steinhart brings significant financial and strategic experience in the biotechnology and medical device industries. Prior to joining BioXcel Therapeutics, Richard served as Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. Prior to joining Remedy Pharmaceuticals, Mr. Steinhart served as an independent consultant to biotechnology and medical device companies. Previously, he was the Senior Vice President, Finance and Chief Financial Officer of MELA Sciences. Prior to joining MELA Sciences, Mr. Steinhart held a variety of senior-level positions at Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies, Emisphere Technologies, Inc., and CW Group, Inc., a venture capital firm focused on medical technology. He began his career at PriceWaterhouseCoopers.

Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc. and Atossa Genetics, Inc. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).

William P. Kane

William P. Kane

Chief Commercial Officer

Prior to joining BTI, Mr. Kane held senior level commercial positions at leading biopharma companies, including Allergan, Pfizer, and Sepracor (now Sunovion Pharmaceuticals), and was an integral part of launching numerous successful brands. These include CELEBREX® for the treatment of arthritis, NAMZARIC® for Alzheimer’s disease, VRAYLAR® for the treatment of schizophrenia and bipolar disorder, and UBRELVY™, the first oral calcitonin gene-related peptide (CGRP) for the acute treatment of migraine. Most recently, he was Senior Vice President and Head of the U.S. General Medicine business unit at Allergan, a multi-therapeutic portfolio with $5.8 billion in 2019 sales, where he oversaw more than 2,000 sales and marketing professionals. Mr. Kane holds a B.A. in Government from Connecticut College and an M.B.A. from the Wharton School at the University of Pennsylvania.